137 related articles for article (PubMed ID: 25621565)
1. Registered report: the CD47-signal regulated protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Chroscinski D; Maherali N; Griner E;
Elife; 2015 Jan; 4():. PubMed ID: 25621565
[TBL] [Abstract][Full Text] [Related]
2. Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Horrigan SK;
Elife; 2017 Jan; 6():. PubMed ID: 28100392
[TBL] [Abstract][Full Text] [Related]
3. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.
Barclay AN; Van den Berg TK
Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318
[TBL] [Abstract][Full Text] [Related]
4. CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis.
Gao L; Chen K; Gao Q; Wang X; Sun J; Yang YG
Oncotarget; 2017 Apr; 8(14):22406-22413. PubMed ID: 27283989
[TBL] [Abstract][Full Text] [Related]
5. The BALB/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment.
Iwamoto C; Takenaka K; Urata S; Yamauchi T; Shima T; Kuriyama T; Daitoku S; Saito Y; Miyamoto T; Iwasaki H; Kitabayashi I; Itoh K; Kishimoto J; Kohda D; Matozaki T; Akashi K
Exp Hematol; 2014 Mar; 42(3):163-171.e1. PubMed ID: 24269920
[TBL] [Abstract][Full Text] [Related]
6. High-Affinity SIRPα Variants Potentiate Antibody Therapy Efficacy.
Cancer Discov; 2013 Jul; 3(7):716. PubMed ID: 23847342
[TBL] [Abstract][Full Text] [Related]
7. Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients.
Nagahara M; Mimori K; Kataoka A; Ishii H; Tanaka F; Nakagawa T; Sato T; Ono S; Sugihara K; Mori M
Clin Cancer Res; 2010 Sep; 16(18):4625-35. PubMed ID: 20705613
[TBL] [Abstract][Full Text] [Related]
8. Expression and Prognostic Significance of CD47-SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer.
Sugimura-Nagata A; Koshino A; Inoue S; Matsuo-Nagano A; Komura M; Riku M; Ito H; Inoko A; Murakami H; Ebi M; Ogasawara N; Tsuzuki T; Takahashi S; Kasugai K; Kasai K; Inaguma S
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33799989
[TBL] [Abstract][Full Text] [Related]
9. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer.
Kaur S; Elkahloun AG; Singh SP; Chen QR; Meerzaman DM; Song T; Manu N; Wu W; Mannan P; Garfield SH; Roberts DD
Oncotarget; 2016 Mar; 7(9):10133-52. PubMed ID: 26840086
[TBL] [Abstract][Full Text] [Related]
10. [Role of CD47 in hematologic malignancies].
Su GH; Zhao YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1631-4. PubMed ID: 24370062
[TBL] [Abstract][Full Text] [Related]
11. On the origin and function of immune 'self' recognition.
van den Berg TK
Immunol Lett; 2010 Jan; 128(1):24-5. PubMed ID: 19808051
[No Abstract] [Full Text] [Related]
12. The CD47-SIRPα signalling system: its physiological roles and therapeutic application.
Murata Y; Kotani T; Ohnishi H; Matozaki T
J Biochem; 2014 Jun; 155(6):335-44. PubMed ID: 24627525
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.
Yu GT; Bu LL; Huang CF; Zhang WF; Chen WJ; Gutkind JS; Kulkarni AB; Sun ZJ
Oncotarget; 2015 Dec; 6(39):42067-80. PubMed ID: 26573233
[TBL] [Abstract][Full Text] [Related]
14. Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis.
Yang H; Shao R; Huang H; Wang X; Rong Z; Lin Y
Cancer Med; 2019 Aug; 8(9):4245-4253. PubMed ID: 31183992
[TBL] [Abstract][Full Text] [Related]
15. Functional elements on SIRPalpha IgV domain mediate cell surface binding to CD47.
Liu Y; Tong Q; Zhou Y; Lee HW; Yang JJ; Bühring HJ; Chen YT; Ha B; Chen CX; Yang Y; Zen K
J Mol Biol; 2007 Jan; 365(3):680-93. PubMed ID: 17070842
[TBL] [Abstract][Full Text] [Related]
16. Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages.
Ide K; Wang H; Tahara H; Liu J; Wang X; Asahara T; Sykes M; Yang YG; Ohdan H
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5062-6. PubMed ID: 17360380
[TBL] [Abstract][Full Text] [Related]
17. SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors.
Alvey CM; Spinler KR; Irianto J; Pfeifer CR; Hayes B; Xia Y; Cho S; Dingal PCPD; Hsu J; Smith L; Tewari M; Discher DE
Curr Biol; 2017 Jul; 27(14):2065-2077.e6. PubMed ID: 28669759
[TBL] [Abstract][Full Text] [Related]
18. Innate immune 'self' recognition: a role for CD47-SIRPalpha interactions in hematopoietic stem cell transplantation.
van den Berg TK; van der Schoot CE
Trends Immunol; 2008 May; 29(5):203-6. PubMed ID: 18394962
[TBL] [Abstract][Full Text] [Related]
19. Membrane mobility and clustering of Integrin Associated Protein (IAP, CD47)--major differences between mouse and man and implications for signaling.
Subramanian S; Tsai R; Sen S; Dahl KN; Discher DE
Blood Cells Mol Dis; 2006; 36(3):364-72. PubMed ID: 16697668
[TBL] [Abstract][Full Text] [Related]
20. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer.
Yoshida K; Tsujimoto H; Matsumura K; Kinoshita M; Takahata R; Matsumoto Y; Hiraki S; Ono S; Seki S; Yamamoto J; Hase K
Cancer Med; 2015 Sep; 4(9):1322-33. PubMed ID: 26077800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
